2025年,中国医药市场迎来了跨国药企战略调整的密集期。百时美施贵宝(BMS)转让中美上海施贵宝制药全部股权,通用电气医疗(GE医疗)酝酿出售中国子公司股权,而阿斯利康、西门子医疗则同步抛出百亿级投资计划。一退一进之间,折射出在中国医药市场政策重塑与产业升级叠加下,跨国药企的生存逻辑正在发生根本性转变。从“收割成熟市场利润”到“押注创新生态价值”,这场战略重构不仅改写着市场竞争格局,更标注着...
Source Link2025年,中国医药市场迎来了跨国药企战略调整的密集期。百时美施贵宝(BMS)转让中美上海施贵宝制药全部股权,通用电气医疗(GE医疗)酝酿出售中国子公司股权,而阿斯利康、西门子医疗则同步抛出百亿级投资计划。一退一进之间,折射出在中国医药市场政策重塑与产业升级叠加下,跨国药企的生存逻辑正在发生根本性转变。从“收割成熟市场利润”到“押注创新生态价值”,这场战略重构不仅改写着市场竞争格局,更标注着...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.